Cargando…

Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins

Active tumor targeting of nanomedicines has recently shown significant improvements in the therapeutic activity of currently existing drug delivery systems, such as liposomal doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have shown that isolated pVIII major coat proteins of the fd-tet filamento...

Descripción completa

Detalles Bibliográficos
Autores principales: Gillespie, James W., Gross, Amanda L., Puzyrev, Anatoliy T., Bedi, Deepa, Petrenko, Valery A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477153/
https://www.ncbi.nlm.nih.gov/pubmed/26157433
http://dx.doi.org/10.3389/fmicb.2015.00628
_version_ 1782377703454801920
author Gillespie, James W.
Gross, Amanda L.
Puzyrev, Anatoliy T.
Bedi, Deepa
Petrenko, Valery A.
author_facet Gillespie, James W.
Gross, Amanda L.
Puzyrev, Anatoliy T.
Bedi, Deepa
Petrenko, Valery A.
author_sort Gillespie, James W.
collection PubMed
description Active tumor targeting of nanomedicines has recently shown significant improvements in the therapeutic activity of currently existing drug delivery systems, such as liposomal doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have shown that isolated pVIII major coat proteins of the fd-tet filamentous phage vector, containing cancer cell-specific peptide fusions at their N-terminus, can be used as active targeting ligands in a liposomal doxorubicin delivery system in vitro and in vivo. Here, we show a novel major coat protein isolation procedure in 2-propanol that allows spontaneous incorporation of the hydrophobic protein core into preformed liposomal doxorubicin with minimal damage or drug loss while still retaining the targeting ligand exposed for cell-specific targeting. Using a panel of 12 structurally unique ligands with specificity toward breast, lung, and/or pancreatic cancer, we showed the feasibility of pVIII major coat proteins to significantly increase the throughput of targeting ligand screening in a common nanomedicine core. Phage protein-modified Lipodox samples showed an average doxorubicin recovery of 82.8% across all samples with 100% of protein incorporation in the correct orientation (N-terminus exposed). Following cytotoxicity screening in a doxorubicin-sensitive breast cancer line (MCF-7), three major groups of ligands were identified. Ligands showing the most improved cytotoxicity included: DMPGTVLP, ANGRPSMT, VNGRAEAP, and ANDVYLD showing a 25-fold improvement (p < 0.05) in toxicity. Similarly DGQYLGSQ, ETYNQPYL, and GSSEQLYL ligands with specificity toward a doxorubicin-insensitive pancreatic cancer line (PANC-1) showed significant increases in toxicity (2-fold; p < 0.05). Thus, we demonstrated proof-of-concept that pVIII major coat proteins can be screened in significantly higher throughput to identify novel ligands displaying improved therapeutic activity in a desired cancer phenotype.
format Online
Article
Text
id pubmed-4477153
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44771532015-07-08 Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins Gillespie, James W. Gross, Amanda L. Puzyrev, Anatoliy T. Bedi, Deepa Petrenko, Valery A. Front Microbiol Microbiology Active tumor targeting of nanomedicines has recently shown significant improvements in the therapeutic activity of currently existing drug delivery systems, such as liposomal doxorubicin (Doxil/Caelyx/Lipodox). Previously, we have shown that isolated pVIII major coat proteins of the fd-tet filamentous phage vector, containing cancer cell-specific peptide fusions at their N-terminus, can be used as active targeting ligands in a liposomal doxorubicin delivery system in vitro and in vivo. Here, we show a novel major coat protein isolation procedure in 2-propanol that allows spontaneous incorporation of the hydrophobic protein core into preformed liposomal doxorubicin with minimal damage or drug loss while still retaining the targeting ligand exposed for cell-specific targeting. Using a panel of 12 structurally unique ligands with specificity toward breast, lung, and/or pancreatic cancer, we showed the feasibility of pVIII major coat proteins to significantly increase the throughput of targeting ligand screening in a common nanomedicine core. Phage protein-modified Lipodox samples showed an average doxorubicin recovery of 82.8% across all samples with 100% of protein incorporation in the correct orientation (N-terminus exposed). Following cytotoxicity screening in a doxorubicin-sensitive breast cancer line (MCF-7), three major groups of ligands were identified. Ligands showing the most improved cytotoxicity included: DMPGTVLP, ANGRPSMT, VNGRAEAP, and ANDVYLD showing a 25-fold improvement (p < 0.05) in toxicity. Similarly DGQYLGSQ, ETYNQPYL, and GSSEQLYL ligands with specificity toward a doxorubicin-insensitive pancreatic cancer line (PANC-1) showed significant increases in toxicity (2-fold; p < 0.05). Thus, we demonstrated proof-of-concept that pVIII major coat proteins can be screened in significantly higher throughput to identify novel ligands displaying improved therapeutic activity in a desired cancer phenotype. Frontiers Media S.A. 2015-06-23 /pmc/articles/PMC4477153/ /pubmed/26157433 http://dx.doi.org/10.3389/fmicb.2015.00628 Text en Copyright © 2015 Gillespie, Gross, Puzyrev, Bedi and Petrenko. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Gillespie, James W.
Gross, Amanda L.
Puzyrev, Anatoliy T.
Bedi, Deepa
Petrenko, Valery A.
Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title_full Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title_fullStr Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title_full_unstemmed Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title_short Combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
title_sort combinatorial synthesis and screening of cancer cell-specific nanomedicines targeted via phage fusion proteins
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477153/
https://www.ncbi.nlm.nih.gov/pubmed/26157433
http://dx.doi.org/10.3389/fmicb.2015.00628
work_keys_str_mv AT gillespiejamesw combinatorialsynthesisandscreeningofcancercellspecificnanomedicinestargetedviaphagefusionproteins
AT grossamandal combinatorialsynthesisandscreeningofcancercellspecificnanomedicinestargetedviaphagefusionproteins
AT puzyrevanatoliyt combinatorialsynthesisandscreeningofcancercellspecificnanomedicinestargetedviaphagefusionproteins
AT bedideepa combinatorialsynthesisandscreeningofcancercellspecificnanomedicinestargetedviaphagefusionproteins
AT petrenkovalerya combinatorialsynthesisandscreeningofcancercellspecificnanomedicinestargetedviaphagefusionproteins